Earnings
|
Reports Q1 revenue $628M,… ShowHide Related Items >><< CENTA Central Garden & Pet - 01/13/23 JPMorgan
- Central Garden & Pet price target lowered to $39 from $40 at JPMorgan
- 10/13/22 JPMorgan
- Central Garden & Pet price target lowered to $37 from $45 at JPMorgan
- 08/25/22 CJS Securities
- Central Garden & Pet initiated with an Outperform at CJS Securities
- 08/08/22 Truist
- Central Garden & Pet price target lowered to $60 from $65 at Truist
CENTA Central Garden & Pet - 11/21/22
- Central Garden & Pet sees FY23 EPS $2.60-$2.80, consensus $2.93
- 11/21/22
- Central Garden & Pet reports Q4 EPS (4c), consensus 1c
- 08/03/22
- Central Garden & Pet sees FY22 EPS at or above prior year
- 08/03/22
- Central Garden & Pet reports Q3 EPS $1.39, consensus $1.27
|
Hot Stocks
| ShowHide Related Items >><< - 06:18 Today
- Amgen announces Humira biosimilar now available in the U.S.
- 01/09/23
- Illumina, Nashville Biosciences announce sequencing agreement with Amgen
- 01/03/23
- Researchers' reanalysis questions mortality data in FOURIER trial
- 12/13/22
- Amgen announces presentation of results from E1910 randomized Phase 3 trial
- 01/19/23 Piper Sandler
- Amgen price target cut at Piper on lower Otezla estimates
- 01/03/23 Barclays
- Research raises 'valid questions' about Amgen's Repatha, says Barclays
- 12/13/22 BMO Capital
- Horizon Therapeutics downgraded to Market Perform from Outperform at BMO Capital
- 12/13/22 Baird
- Amgen deal yields nice accretion but large debt position, says Baird
- 16:02 Today
- Amgen sees FY23 adjusted EPS $17.40-$18.60, consensus $18.33
- 16:02 Today
- Amgen sees FY23 adjusted EPS $17.40-$18.60, consensus $18.33
- 16:01 Today
- Amgen reports Q4 adjusted EPS $4.09, consensus $4.09
- 13:20 Today
- Notable companies reporting after market close
- 06:26 Today
- AbbVie's Humira drug faces competition in the U.S., FT reports
- 01/30/23
- Amgen lays off 300 employees, or 1.2% of workforce, Reuters reports
- 01/26/23
- Warren writes FTC over concerns of two pharma deals, Reuters reports
- 12/11/22
- Amgen nears deal to acquire Horizon Therapeutics, WSJ reports
- 01/30/23
- What You Missed On Wall Street On Monday
- 01/30/23
- What You Missed On Wall Street This Morning
- 12/13/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/12/22
- What You Missed On Wall Street On Monday
- 14:04 Today
- Amgen options imply 3.2% move in share price post-earnings
- 10/11/22
- Early notable gainers among liquid option names on October 11th
|
Earnings
| ShowHide Related Items >><< - 01/19/23
- Sony announces additional games coming to PlayStation VR2
- 01/17/23
- U.S. video game consumer spending rose 2% y/y in December, says NPD
- 01/17/23
- 'Call of Duty: Modern Warfare 2' top game seller in U.S. in December, says NPD
- 11/21/22
- Electronic Arts CEO Wilson sells 10,000 common shares
- 01/27/23 Wedbush
- Electronic Arts initiated with an Outperform at Wedbush
- 01/27/23 Credit Suisse
- Electronic Arts price target raised to $154 from $143 at Credit Suisse
- 01/25/23 Barclays
- Electronic Arts price target raised to $132 from $130 at Barclays
- 01/17/23 Benchmark
- Electronic Arts price target lowered to $150 from $188 at Benchmark
- 16:02 Today
- Electronic Arts reports Q3 EPS 73, consensus $3.05
- 13:20 Today
- Notable companies reporting after market close
- 11/01/22
- Electronic Arts raises FY23 EPS view to $3.11-$3.34 from $2.79-$2.87
- 11/01/22
- Electronic Arts sees Q3 EPS 43c-59c, consensus $3.01
- 01/30/23
- EA's 'Dead Space' top-selling physical game in U.K., GI.biz says
- 01/23/23
- Nintendo's new 'Fire Emblem' top-selling physical game in U.K., GI.biz says
- 01/18/23
- Video game sales fell 13% y/y in Europe in December, GI.biz says
- 01/11/23
- Amazon Game Studios loses another key executive amid cutbacks, Bloomberg says
- 13:51 Today
- What You Missed This Week in Video Games
- 01/24/23
- What You Missed This Week in Video Games
- 01/17/23
- What You Missed This Week in Video Games
- 01/10/23
- What You Missed This Week in Video Games
- 14:34 Today
- Electronic Arts options imply 4.3% move in share price post-earnings
- 10/05/22
- Electronic Arts put volume heavy and directionally bearish
- 10/03/22
- Electronic Arts Inc. call volume above normal and directionally bullish
- 08/26/22
- Early notable gainers among liquid option names on August 26th
|
Earnings
| ShowHide Related Items >><< - 06:18 Today
- Amgen announces Humira biosimilar now available in the U.S.
- 01/09/23
- Illumina, Nashville Biosciences announce sequencing agreement with Amgen
- 01/03/23
- Researchers' reanalysis questions mortality data in FOURIER trial
- 12/13/22
- Amgen announces presentation of results from E1910 randomized Phase 3 trial
- 01/19/23 Piper Sandler
- Amgen price target cut at Piper on lower Otezla estimates
- 01/03/23 Barclays
- Research raises 'valid questions' about Amgen's Repatha, says Barclays
- 12/13/22 BMO Capital
- Horizon Therapeutics downgraded to Market Perform from Outperform at BMO Capital
- 12/13/22 Baird
- Amgen deal yields nice accretion but large debt position, says Baird
- 16:02 Today
- Amgen sees FY23 adjusted EPS $17.40-$18.60, consensus $18.33
- 16:01 Today
- Amgen reports Q4 adjusted EPS $4.09, consensus $4.09
- 13:20 Today
- Notable companies reporting after market close
- 11/03/22
- Amgen narrows FY22 adjusted EPS view to $17.25-$17.85 from $17.00-$18.00
- 06:26 Today
- AbbVie's Humira drug faces competition in the U.S., FT reports
- 01/30/23
- Amgen lays off 300 employees, or 1.2% of workforce, Reuters reports
- 01/26/23
- Warren writes FTC over concerns of two pharma deals, Reuters reports
- 12/11/22
- Amgen nears deal to acquire Horizon Therapeutics, WSJ reports
- 01/30/23
- What You Missed On Wall Street On Monday
- 01/30/23
- What You Missed On Wall Street This Morning
- 12/13/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/12/22
- What You Missed On Wall Street On Monday
- 14:04 Today
- Amgen options imply 3.2% move in share price post-earnings
- 10/11/22
- Early notable gainers among liquid option names on October 11th
|
Earnings
| ShowHide Related Items >><< - 06:18 Today
- Amgen announces Humira biosimilar now available in the U.S.
- 01/09/23
- Illumina, Nashville Biosciences announce sequencing agreement with Amgen
- 01/03/23
- Researchers' reanalysis questions mortality data in FOURIER trial
- 12/13/22
- Amgen announces presentation of results from E1910 randomized Phase 3 trial
- 01/19/23 Piper Sandler
- Amgen price target cut at Piper on lower Otezla estimates
- 01/03/23 Barclays
- Research raises 'valid questions' about Amgen's Repatha, says Barclays
- 12/13/22 BMO Capital
- Horizon Therapeutics downgraded to Market Perform from Outperform at BMO Capital
- 12/13/22 Baird
- Amgen deal yields nice accretion but large debt position, says Baird
- 16:01 Today
- Amgen reports Q4 adjusted EPS $4.09, consensus $4.09
- 13:20 Today
- Notable companies reporting after market close
- 11/03/22
- Amgen narrows FY22 adjusted EPS view to $17.25-$17.85 from $17.00-$18.00
- 11/03/22
- Amgen reports Q3 adjusted EPS $4.70, consensus $4.44
- 06:26 Today
- AbbVie's Humira drug faces competition in the U.S., FT reports
- 01/30/23
- Amgen lays off 300 employees, or 1.2% of workforce, Reuters reports
- 01/26/23
- Warren writes FTC over concerns of two pharma deals, Reuters reports
- 12/11/22
- Amgen nears deal to acquire Horizon Therapeutics, WSJ reports
- 01/30/23
- What You Missed On Wall Street On Monday
- 01/30/23
- What You Missed On Wall Street This Morning
- 12/13/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/12/22
- What You Missed On Wall Street On Monday
- 14:04 Today
- Amgen options imply 3.2% move in share price post-earnings
- 10/11/22
- Early notable gainers among liquid option names on October 11th
|
Earnings
| ShowHide Related Items >><< - 01/19/23
- Sony announces additional games coming to PlayStation VR2
- 01/17/23
- U.S. video game consumer spending rose 2% y/y in December, says NPD
- 01/17/23
- 'Call of Duty: Modern Warfare 2' top game seller in U.S. in December, says NPD
- 11/21/22
- Electronic Arts CEO Wilson sells 10,000 common shares
- 01/27/23 Wedbush
- Electronic Arts initiated with an Outperform at Wedbush
- 01/27/23 Credit Suisse
- Electronic Arts price target raised to $154 from $143 at Credit Suisse
- 01/25/23 Barclays
- Electronic Arts price target raised to $132 from $130 at Barclays
- 01/17/23 Benchmark
- Electronic Arts price target lowered to $150 from $188 at Benchmark
- 13:20 Today
- Notable companies reporting after market close
- 11/01/22
- Electronic Arts raises FY23 EPS view to $3.11-$3.34 from $2.79-$2.87
- 11/01/22
- Electronic Arts sees Q3 EPS 43c-59c, consensus $3.01
- 11/01/22
- Electronic Arts reports Q2 EPS $1.07, consensus $1.37
- 01/30/23
- EA's 'Dead Space' top-selling physical game in U.K., GI.biz says
- 01/23/23
- Nintendo's new 'Fire Emblem' top-selling physical game in U.K., GI.biz says
- 01/18/23
- Video game sales fell 13% y/y in Europe in December, GI.biz says
- 01/11/23
- Amazon Game Studios loses another key executive amid cutbacks, Bloomberg says
- 13:51 Today
- What You Missed This Week in Video Games
- 01/24/23
- What You Missed This Week in Video Games
- 01/17/23
- What You Missed This Week in Video Games
- 01/10/23
- What You Missed This Week in Video Games
- 14:34 Today
- Electronic Arts options imply 4.3% move in share price post-earnings
- 10/05/22
- Electronic Arts put volume heavy and directionally bearish
- 10/03/22
- Electronic Arts Inc. call volume above normal and directionally bullish
- 08/26/22
- Early notable gainers among liquid option names on August 26th
|
General news
| ShowHide Related Items >><< - 01/30/23
- Fed likely to raise funds rate benchmark by quarter percentage point, WSJ says
- 01/22/23
- Fed sets course for milder interest-rate rise next month, WSJ says
- 11/04/22
- Fed's Evans says smaller rate hikes make sense, Reuters reports
- 10/22/22
- Fed set to raise rates by 0.75 point, discuss size of future hikes, WSJ says
- 01/24/23
- What You Missed On Wall Street On Tuesday
- 01/18/23
- What You Missed On Wall Street On Wednesday
- 12/15/22
- What You Missed On Wall Street On Thursday
- 12/15/22
- What You Missed On Wall Street This Morning
|
General news
| ShowHide Related Items >><< - 01/30/23
- Fed likely to raise funds rate benchmark by quarter percentage point, WSJ says
- 01/22/23
- Fed sets course for milder interest-rate rise next month, WSJ says
- 11/04/22
- Fed's Evans says smaller rate hikes make sense, Reuters reports
- 10/22/22
- Fed set to raise rates by 0.75 point, discuss size of future hikes, WSJ says
- 01/24/23
- What You Missed On Wall Street On Tuesday
- 01/18/23
- What You Missed On Wall Street On Wednesday
- 12/15/22
- What You Missed On Wall Street On Thursday
- 12/15/22
- What You Missed On Wall Street This Morning
|
Earnings
|
Reports Q4 revenue $6.8B,… ShowHide Related Items >><< - 06:18 Today
- Amgen announces Humira biosimilar now available in the U.S.
- 01/09/23
- Illumina, Nashville Biosciences announce sequencing agreement with Amgen
- 01/03/23
- Researchers' reanalysis questions mortality data in FOURIER trial
- 12/13/22
- Amgen announces presentation of results from E1910 randomized Phase 3 trial
- 01/19/23 Piper Sandler
- Amgen price target cut at Piper on lower Otezla estimates
- 01/03/23 Barclays
- Research raises 'valid questions' about Amgen's Repatha, says Barclays
- 12/13/22 BMO Capital
- Horizon Therapeutics downgraded to Market Perform from Outperform at BMO Capital
- 12/13/22 Baird
- Amgen deal yields nice accretion but large debt position, says Baird
- 13:20 Today
- Notable companies reporting after market close
- 11/03/22
- Amgen narrows FY22 adjusted EPS view to $17.25-$17.85 from $17.00-$18.00
- 11/03/22
- Amgen reports Q3 adjusted EPS $4.70, consensus $4.44
- 11/03/22
- Notable companies reporting after market close
- 06:26 Today
- AbbVie's Humira drug faces competition in the U.S., FT reports
- 01/30/23
- Amgen lays off 300 employees, or 1.2% of workforce, Reuters reports
- 01/26/23
- Warren writes FTC over concerns of two pharma deals, Reuters reports
- 12/11/22
- Amgen nears deal to acquire Horizon Therapeutics, WSJ reports
- 01/30/23
- What You Missed On Wall Street On Monday
- 01/30/23
- What You Missed On Wall Street This Morning
- 12/13/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/12/22
- What You Missed On Wall Street On Monday
- 14:04 Today
- Amgen options imply 3.2% move in share price post-earnings
- 10/11/22
- Early notable gainers among liquid option names on October 11th
|
Hot Stocks
|
Kushner, which identifies… ShowHide Related Items >><< - 01/19/23
- Veris Residential shareholder Kushner responds to Veris Board statement
- 01/18/23
- Veris Residential falls 9% to $14.88 after Kushner Co. pulls out of deal talks
- 01/18/23
- Veris Residential issues statement on strategic alternatives
- 01/18/23
- Veris Residential forms strategic partnership with the MIT
- 01/19/23 BTIG
- BTIG continues to see value in Veris Residential
- 12/13/22 BTIG
- Veris Residential price target lowered to $22 from $26 at BTIG
- 11/14/22 BofA
- Veris Residential upgraded to Neutral at BofA in residential REIT repositioning
- 11/14/22 BofA
- Veris Residential upgraded to Neutral from Underperform at BofA
- 08/03/22
- Veris Residential reports Q2 core FFO 15c, consensus 12c
- 11/22/22
- Fortress agrees to finance Kushner bid to acquire Veris Residential, WSJ says
- 10/21/22
- What You Missed On Wall Street On Friday
- 10/21/22
- What You Missed On Wall Street This Morning
- 10/21/22
- Fly Intel: Pre-market Movers
|